Literature DB >> 35410525

Pink1 promotes cell proliferation and affects glycolysis in breast cancer.

Jing Li1, Xuting Xu1, Huilian Huang1, Liqin Li1, Jing Chen1, Yunfeng Ding2, Jinliang Ping3.   

Abstract

Phosphatase and tensin homolog (PTEN)-induced kinase 1 (Pink1) is regarded as a tumor suppressor and plays an important role in cancer cell biology, while relatively few studies have examined Pink1 in breast cancer, especially in vivo. The aims of this study were to investigate Pink1 expression in different subtypes of breast cancer tissues and cell lines and explore the effect of Pink1 protein on breast cancer. In these experiments, Pink1 expression was investigated using the tissue microarray immunohistochemistry (TMA-IHC) method in 150 samples of breast cancer tissues with different subtypes, and strong staining of Pink1 was significantly correlated with the histological grade of breast cancer (p = 0.015). In addition, Pink1 messenger RNA (mRNA) displayed much higher expression levels in breast cancer cell lines than in MCF-10A breast epithelial cells. Moreover, proteomic data obtained by isobaric tags for relative and absolute quantification (iTRAQ) showed that Pink1 deletion induced a distinct proteomic profile in MDA-MB-231 cells, and enrichment analysis showed that the differential proteins were concentrated mainly in energy metabolism-related pathways. Moreover, Seahorse XF analysis showed that Pink1 knockout reduced the glycolytic ability of MDA-MB-231 cells. Our findings indicated that Pink1 may be an indicator of malignancy in breast cancer and that it presents oncogenic properties in breast cancer, which raises another perspective for understanding the regulatory role of Pink1 in breast cancer.

Entities:  

Keywords:  MDA-MB-231; Pink1; breast cancer; glycolysis; immunohistochemistry

Mesh:

Year:  2022        PMID: 35410525      PMCID: PMC9265526          DOI: 10.1177/15353702221082613

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  33 in total

1.  PINK1 Is a Negative Regulator of Growth and the Warburg Effect in Glioblastoma.

Authors:  Sameer Agnihotri; Brian Golbourn; Xi Huang; Marc Remke; Susan Younger; Rob A Cairns; Alan Chalil; Christian A Smith; Stacey-Lynn Krumholtz; Danielle Mackenzie; Patricia Rakopoulos; Vijay Ramaswamy; Michael S Taccone; Paul S Mischel; Gregory N Fuller; Cynthia Hawkins; William L Stanford; Michael D Taylor; Gelareh Zadeh; James T Rutka
Journal:  Cancer Res       Date:  2016-06-20       Impact factor: 12.701

2.  Phylogenetic and in silico structural analysis of the Parkinson disease-related kinase PINK1.

Authors:  Fernando Cardona; Jose Vicente Sánchez-Mut; Hernán Dopazo; Jordi Pérez-Tur
Journal:  Hum Mutat       Date:  2011-04       Impact factor: 4.878

3.  Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies.

Authors:  Selvaraju Veeriah; Barry S Taylor; Shasha Meng; Fang Fang; Emrullah Yilmaz; Igor Vivanco; Manickam Janakiraman; Nikolaus Schultz; Aphrothiti J Hanrahan; William Pao; Marc Ladanyi; Chris Sander; Adriana Heguy; Eric C Holland; Philip B Paty; Paul S Mischel; Linda Liau; Timothy F Cloughesy; Ingo K Mellinghoff; David B Solit; Timothy A Chan
Journal:  Nat Genet       Date:  2009-11-29       Impact factor: 38.330

Review 4.  The biology of cancer: metabolic reprogramming fuels cell growth and proliferation.

Authors:  Ralph J DeBerardinis; Julian J Lum; Georgia Hatzivassiliou; Craig B Thompson
Journal:  Cell Metab       Date:  2008-01       Impact factor: 27.287

5.  Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism.

Authors:  Laura Silvestri; Viviana Caputo; Emanuele Bellacchio; Luigia Atorino; Bruno Dallapiccola; Enza Maria Valente; Giorgio Casari
Journal:  Hum Mol Genet       Date:  2005-10-05       Impact factor: 6.150

6.  Targeting PINK1 and MQC in brain tumors.

Authors:  Kyu-Sun Lee; Bingwei Lu
Journal:  Oncotarget       Date:  2014-05-30

7.  BRCA1 degradation in response to mitochondrial damage in breast cancer cells.

Authors:  Kana Miyahara; Naoharu Takano; Yumiko Yamada; Hiromi Kazama; Mayumi Tokuhisa; Hirotsugu Hino; Koji Fujita; Edward Barroga; Masaki Hiramoto; Hiroshi Handa; Masahiko Kuroda; Takashi Ishikawa; Keisuke Miyazawa
Journal:  Sci Rep       Date:  2021-04-22       Impact factor: 4.379

8.  PINK1 drives production of mtDNA-containing extracellular vesicles to promote invasiveness.

Authors:  Nicolas Rabas; Sarah Palmer; Louise Mitchell; Shehab Ismail; Andrea Gohlke; Joel S Riley; Stephen W G Tait; Payam Gammage; Leandro Lemgruber Soares; Iain R Macpherson; Jim C Norman
Journal:  J Cell Biol       Date:  2021-10-08       Impact factor: 10.539

9.  Hereditary early-onset Parkinson's disease caused by mutations in PINK1.

Authors:  Enza Maria Valente; Patrick M Abou-Sleiman; Viviana Caputo; Miratul M K Muqit; Kirsten Harvey; Suzana Gispert; Zeeshan Ali; Domenico Del Turco; Anna Rita Bentivoglio; Daniel G Healy; Alberto Albanese; Robert Nussbaum; Rafael González-Maldonado; Thomas Deller; Sergio Salvi; Pietro Cortelli; William P Gilks; David S Latchman; Robert J Harvey; Bruno Dallapiccola; Georg Auburger; Nicholas W Wood
Journal:  Science       Date:  2004-04-15       Impact factor: 47.728

10.  TRIM11 promotes proliferation and glycolysis of breast cancer cells via targeting AKT/GLUT1 pathway.

Authors:  WenBo Song; Zheng Wang; Xiang Gu; ALi Wang; XiaoJun Chen; Hui Miao; JunFeng Chu; Ye Tian
Journal:  Onco Targets Ther       Date:  2019-06-28       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.